Key result
Administration of ANGPTL4 recombinant protein mitigated acute rejection in a rat liver transplantation model by promoting Kupffer cell M2 polarization and inhibiting the NF-κB signaling pathway.
Why the study?
Acute rejection is a significant complication in liver transplantation influenced by Kupffer cell polarization, prompting investigation into the role of ANGPTL4 in modulating Kupffer cell polarization through hepatocyte-Kupffer cell interactions.
Does ANGPTL4 recombinant protein improve liver function and suppress inflammation in a rat liver transplantation model?
Does ANGPTL4 recombinant protein improve liver function and suppress inflammation in a rat liver transplantation model?
ANGPTL4 recombinant protein mitigates acute rejection in a rat liver transplantation model by promoting Kupffer cell M2 polarization via NF-κB inhibition.
Hypothesis-generating in rat liver transplant rejection; leaves open translation to human clinical use.
Acute rejection (AR) is a significant complication in liver transplantation, impacting graft function and patient survival. Kupffer cells (KCs), liver-specific macrophages, can polarize into pro-inflammatory M1 or anti-inflammatory M2 phenotypes, both of which critically influence AR outcomes. Angiopoietin-like 4 (ANGPTL4), a secretory protein, is recognized for its function in regulating inflammation and macrophage polarization. This study investigates the effects of ANGPTL4 on KC polarization through cellular interactions between hepatocytes (HCs) and KCs. Using a rat orthotopic liver transplantation model, we observed reduced ANGPTL4 expression during AR, whereas increased ANGPTL4 levels were linked to immune tolerance. Administration of ANGPTL4 recombinant protein improved liver function, suppressed inflammation, and promoted M2 polarization of KCs. Co-culture experiments demonstrated that hepatocyte-derived ANGPTL4 significantly modulates KC polarization and inflammatory responses, mainly by inhibiting the NF-κB signaling pathway. The results emphasize the promise of ANGPTL4 as a therapeutic target to reduce AR and improve liver transplant outcomes by influencing hepatocyte-KC interactions.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2025) studied Acute rejection in liver transplantation. ANGPTL4 recombinant protein vs. PBS or untreated acute rejection control was evaluated on Acute rejection severity (RAI score, liver enzymes, apoptosis, and inflammatory cytokines). Administration of ANGPTL4 recombinant protein mitigated acute rejection in a rat liver transplantation model by promoting Kupffer cell M2 polarization and inhibiting the NF-κB signaling pathway.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: